EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION I
12:30 – 14:15
WELCOME & FIRST PLENARY SESSION
WELCOME & PRESENTATION OF ISPOR SERVICE AWARDS
Scott Ramsey MD, PhD
2010-2011 ISPOR President & Full Member and Professor, Fred Hutchinson Cancer Research Center, University of Washington,
Seattle, WA, USA
CONGRESS INTRODUCTION AND OBJECTIVES
Jan Švihovec MD, PhD, DrSc, Professor, Head of Department of Pharmacology, 2nd Medical Faculty, Charles University & President, ISPOR Czech Republic Regional Chapter, Prague, Czech Republic
F. Cankat Tulunay MD, PhD, Professor, Department of Clinical Pharmacology, Medical School of Ankara University & President, ISPOR Turkey Regional Chapter, Ankara, Turkey
IMPROVING THE EFFICIENCY IN ASSESSMENT OF HEALTH TECHNOLOGY IN EUROPE
Inefficiencies in the assessment of health technology in Europe include redundancy of assessments across countries or local regions, diverse or even conflicting technical & statutory requirements, clear definitions of the clinical outcome, methodological hurdles, timing of assessment, and more. Developing and increasing the efficiency of assessment of health technology across Europe addresses issues of strategic importance. A recent initiative launched jointly by the European Commission and European Union Member States to improve the efficiency in assessment of health technology is the EUnetHTA Joint Action (JA). The objective of the Joint Action on HTA, which includes work on relative effectiveness of pharmaceuticals, is to put into practice an effective and sustainable HTA collaboration in Europe that brings added value at the European, national and regional level. During this plenary session, the inefficiencies in the assessment of health technology in Europe will be identified, the new JA strategy including work on relative effectiveness of pharmaceuticals (REP) will be presented, and a stakeholder’s perspective on the HTA inefficiencies in Europe as well as the new JA strategy and REP will be presented, followed by an open discussion.
Assessment of Health Technology in Europe: Taking Stock of the Inefficiencies
Moderator/Speaker: Bengt Jonsson PhD, Professor of Health Economics, Centre for Health Economics, Stockholm School of Economics, Stockholm, Sweden
The European Network for HTA (EUnetHTA) Joint Action Strategy & Core Model
Speaker:Finn Børlum Kristensen MD, PhD, Director and Coordinating Secretariat, European network for Health Technology Assessment (EUnetHTA) & Chairman of the EUnetHTA Executive Committee, Copenhagen, Denmark
Relative Effectiveness Assessment of Pharmaceuticals: A EUnetHTA Joint Action Initiative
Speaker: Wim Goettsch PhD, Deputy Secretary of the Medicinal Products Reimbursement Committee and European network for Health Technology Assessment (EUnetHTA) Partner, Health Care Insurance Board (CVZ), Diemen, The Netherlands
A Stakeholder Perspective on HTA Inefficiencies in Europe and the HTA Joint Action Initiative
Break, Exhibits & RESEARCH POSTER PRESENTATIONS Viewing – Session I
14:45 – 15:45
ISSUE PANELS – SESSION I
14:45 – 15:45
Health Policy Development Using Outcomes Research Issues IP1: ARE DIAGNOSTICS AND PERSONALIZED MEDICINE IN FLUX? IMPLICATIONS OF GLOBAL POLICY CHANGES FOR HEALTH ECONOMICS AND OUTCOMES RESEARCH Moderator: Eric Faulkner MPH, Senior Director, RTI Health Solutions, Research Triangle Park, NC, USA Panelists: Adrian Towse MA, Director, Office of Health Economics, London, UK; Diego Ossa MD, Head of Health Economics, Molecular Diagnostics, Novartis Pharma AG, Basel, Switzerland; Uwe Siebert MD, MPH, MSc, ScD, Professor and Head, Department of Public Health, Medical Decision Making and Health Technology Assessment, University of Health Sciences, Medical Informatics and Technology, Hall/Innsbruck, Austria
14:45 – 15:45
IP2: METHODS OR PRAGMATISM: WHO SHOULD HAVE THE SAY IN HEALTH ECONOMIC ASSESSMENT? Moderator: J. Jaime Caro MD, Senior Vice President of Health Economics, United BioSource Corporation, Lexington, MA, USA Panelists: Andreas Gerber MD, PhD, Head, Department of Health Economics, Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany; Lise Rochaix PhD, Professor, Commission d'évaluation économique et de santé publique (CEESP), Haute Autorite de Sante, Saint-Denis La Plaine, France; Gert Jan van der Wilt PhD, Professor, Department of Epidemiology, Biostatistics and HTA, Radboud University Medical Centre, Nijmegen, The Netherlands
14:45 – 15:45
IP3: THE VALUE OF A QALY: IS THERE A SINGLE THRESHOLD VALUE OR DOES CONTEXT MATTER? Moderator: F. Reed Johnson PhD, Distinguished Fellow and Principal Economist, RTI Health Solutions, Research Triangle Park, NC, USA Panelists: Nancy Devlin PhD, Research Director, Office of Health Economics, London, UK; MA Koopmanschap PhD, Associate Professor, Institute of Health Policy and Management, Erasmus University, Rotterdam, The Netherlands; Sandra Erntoft PhD, Project Manager, The Swedish Institute for Health Economics (IHE), Lund, Sweden
Patient-Reported Outcomes Research Issues IP5: IS ANY DATA BETTER THAN NO DATA? THE USE OF MIXED MODALITIES FOR PRO DATA COLLECTION IN CLINICAL TRIALS Moderator: Sonya Eremenco MA, e-PRO Manager, United BioSource Corporation, Bethesda, MD, USA Panelists: Stephen Joel Coons PhD, Director, Patient-Reported Outcomes (PRO) Consortium, Critical Path Institute, Tucson, AZ, USA; Ethan Basch MD, MSc, Principal Investigator, Health Outcomes Group, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; Tara Symonds PhD, Senior Director, PRO Centre of Excellence, Global Market Access, PCBU, Pfizer Ltd, Sandwich, Kent, UK
16:00 – 17:00
WORKSHOPS – SESSION I
16:00 - 17:00
Clinical Outcomes Research W1: CONDUCTING & INTERPRETING INDIRECT TREATMENT COMPARISON AND NETWORK META-ANALYSIS: LEARNING THE BASICS Discussion Leaders: Jeroen P. Jansen PhD, MSc, Research Director, Mapi Values, Boston, MA, USA; Neil Hawkins PhD, Director, Oxford Outcomes Ltd, Oxford, UK; Joseph C. Cappelleri PhD, MPH, Pfizer Inc, New London, CT, USA; Rachael Fleurence PhD, Senior Research Scientist and Director, Practice for Evidence Review and Synthesis, United BioSource Corporation, Bethesda, MD, USA
16:00 - 17:00
Economic Outcomes Research W2: THE IMPACT OF DISEASE ON CAREGIVERS: A FORGOTTEN ASPECT OF THE NICE REFERENCE CASE Discussion Leaders: Andrew Lloyd DPhil, Director, Oxford Outcomes Ltd., Oxford, UK; Deven Chauhan PharmD, MSc, Senior Health Economist, Merck, Serono, Feltham, UK; Sarah Acaster MSc, Senior Outcomes Researcher, Oxford Outcomes Ltd, Oxford, UK; Louise Longworth PhD, Reader in Health Economics, Health Economics Research Group, Brunel University, Middlesex, UK
16:00 - 17:00
W3: METHODS IN ECONOMIC ANALYSIS OF PATIENT SUPPORT PROGRAMS IN AGING Discussion Leaders: Laura T. Pizzi PharmD, MPH, Associate Professor and Program Director, Health Economics and Outcomes Research, Jefferson School of Population Health, Thomas Jefferson University, Philadelphia, PA, USA; Eric Jutkowitz, Post Baccalaureate Fellow, Jefferson School of Population Health, Thomas Jefferson University, Philadelphia, PA, USA; Laura Gitlin PhD, Director, Jefferson Center for Applied Research on Aging and Health, Thomas Jefferson University, Philadelphia, PA, USA; Dong-Churl Suh PhD, MBA, Professor, School of Pharmacy, Rutgers University, Piscataway, NJ, USA
16:00 - 17:00
Health Care Policy Development Using Outcomes Research W4: HTA INFLUENCE MAPPING: SOURCING THE PRIMARY OPINION Discussion Leaders: Cyrus Chowdhury MSc, Vice President, Global Market Access, Insight Strategy Advisors, New York City, NY, USA; Corinna Sorenson MPH, MHSA, Research Officer, European Health Policy, Health & Social Care, London School of Economics, London, UK; Monica Martin de Bustamante, Principal, Global Market Access, Insight Strategy Advisors, New York City, NY, USA
16:00 - 17:00
W5: HOW TO ADDRESS REGIONAL MARKET ACCESS HURDLES IN DECENTRALISED EUROPEAN COUNTRIES Discussion Leaders: Mondher Toumi PhD, MD, Professor of Decision Sciences, UFR d'Odontologie, University Claude Bernard Lyon 1, Lyon, Rhone Alpes, France; Claudio Jommi, Associate Professor, Università del Piemonte Orientale and Pharmaceutical Observatory, Cergas, University of Bocconi, Milano, Italy; Steven Flostrand MBA, Business Development Director, Creativ-Ceutical, Paris, France
Clinical Outcomes Research W8: UNDERSTANDING MIXED TREATMENT COMPARISONS (MTCS): WHAT DO THE RESULTS MEAN AND HOW SHOULD THEY BE USED? Discussion Leaders:Rachael Fleurence PhD, Senior Research Scientist and Director, Practice for Evidence Review and Synthesis, United BioSource Corporation, Bethesda, MD, USA; Kyle Fahrbach PhD, Senior Biostatistician, United BioSource Corporation, Lexington, MA, USA; David Vanness PhD, Assistant Professor, Department of Population Health Sciences, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
17:15 – 18:15
Economic Outcomes Research W9: CONSIDERING HEALTH AS AN INVESTMENT RATHER THAN A COST – ALTERNATIVE MODELLING APPROACHES TO DEMONSTRATE ECONOMIC VALUE Discussion Leaders: Olivier Ethgen MSc, PhD, Associate Professor of Health Economics, Department of Public Health Sciences, University of Liège, Liège, Belgium; Mark Connolly PhD, Managing Director, Global Market Access Solutions, St. Prex, Switzerland; Maarten J. Postma PhD, Professor of Pharmacoeconomics, University of Groningen, Groningen, The Netherlands
17:15 – 18:15
W10: COMPARING MULTIPLE STRATEGIES IN COST-EFFECTIVENESS ANALYSES Discussion Leaders: Aline Gauthier MSc, Director, Amaris, London, UK; Sibilia Quilici MSc, Health Economics Manager, Sanofi Pasteur MSD, Lyon, France; Lieven Annemans PhD, MSc, Professor, Centre for Health Economics Research and Health Economist, I-CHER, University of Ghent, Ghent, Belgium
17:15 – 18:15
Health Care Policy Development Using Outcomes Research W11: FINANCING COORDINATED CARE IN THE EUROPEAN UNION Discussion Leaders: Volker Amelung PhD, Professor, Medical School Hannover (MHH), Hannover, Germany; Robert Berenson MD, Institute Fellow at the Urban Institute, The Urban Institute, Washington, DC, USA; Axel Christian Mühlbacher PhD, Professor for Health Economics, IGM Institute Health Economics and Health Care Management, HS Neubrandenburg, Neubrandenburg, Germany; Giacomo Pignataro PhD, Professor of Health Economics, Università di Catania, Catania, Italy
17:15 – 18:15
W12: RELATIVE EFFICACY: THE POSSIBLE NEW FRONTIER? Discussion Leaders: Monique Martin MBA, MSc, Vice President, UK Operations, i3 Innovus, Uxbridge, Middlesex, UK; Benedikte Lensberg MSc, Project Leader, HEOR Uxbridge, i3 Innovus, Uxbridge, Middlesex, UK; Michael Drummond PhD, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK
17:15 – 18:15
Patient-Reported Outcomes Research W13: MODERN METHODS OF UTILITY MEASUREMENT Discussion Leaders: Paul Krabbe PhD, Principal Investigator, Epidemiology, Biostatistics & Health Technology Assessment, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; Nancy Devlin PhD, Research Director, Office of Health Economics, London, UK
17:15 – 18:15
Use of Real World Data W14: ENSURING EXTERNAL VALIDITY IN OBSERVATIONAL RESEARCH Discussion Leaders: Eric Gemmen MA, Senior Director, Medical Affairs, Epidemiology & Outcomes Research, Quintiles, Rockville, MD, USA; Louise Parmenter PhD, Senior Director, Late Phase Strategy and Planning, Quintiles Limited, Bracknell, Berkshire, UK; Anne Marciniak MD, MPhil, MBA, Director, Evidence Lead, International Health Economics, Amgen Limited, Uxbridge, UK; Jean-Louis Merot MD, Senior Director, Late Phase Project Management, Quintiles, Levallois-Perret, France
18:15 – 19:15
POSTER AUTHOR DISCUSSION HOUR – SESSION I
18:15 – 20:00
Exhibitors’ Open House Reception
19:00 – 20:00
EDUCATIONAL SYMPOSIUM - Sponsored by ISPOR & EUnetHTA
TOOLS AND METHODS FOR CROSS-BORDER COLLABORATION IN HTA
